Enhertu Approved for HER2-Low Metastatic Breast Cancer
The FDA has approved Enhertu (fam-trastuzumab-deruxtecan-nxki) for adults with unresectable or metastatic HER2-low breast cancer.
Source: cancertherapyadvisor.com
📰 Boxed Warning News
Page 42 - Boxed Warning News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Boxed Warning. Real-time updates on events, politics, business and more.
Enhertu Approved for HER2-Low Metastatic Breast Cancer
The FDA has approved Enhertu (fam-trastuzumab-deruxtecan-nxki) for adults with unresectable or metastatic HER2-low breast cancer.
Source: empr.com
Myovant Sciences and Pfizer Receive U.S. FDA Approval of
Data from the Phase 3 SPIRIT program showed MYFEMBREE reduced menstrual pain and non-menstrual pelvic pain in premenopausal women with endometriosis, and a...
Source: globenewswire.com
Myovant Sciences and Pfizer Receive U.S. FDA Approval of MYFEMBREE, a Once-Daily Treatment for the Management of Moderate to Severe Pain Associated With Endometriosis
06.08.2022 - Data from the Phase 3 SPIRIT program showed MYFEMBREE reduced menstrual pain and non-menstrual pelvic pain in premenopausal women with endometriosis, and a loss of mean bone mineral density of less than 1% from baseline through one year of treatment ...
Source: wallstreet-online.de
FDA Approves Oral Testosterone Replacement Therapy Kyzatrex
Kyzatrex is a Schedule III controlled substance.
Source: renalandurologynews.com
Ardelyx Reports Second Quarter 2022 Financial Results and Recent Business Highlights
/PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative...
Source: prnewswire.com
FDA Approves Oral Testosterone Replacement Therapy Kyzatrex
Kyzatrex is a Schedule III controlled substance.
Source: empr.com
Aurinia Announces Positive CHMP Opinion for LUPKYNIS® (voclosporin) for the Treatment of Adults with Active Lupus Nephritis in Europe
Press release content from Business Wire. The AP news staff was not involved in its creation.
Source: apnews.com
Aurinia Pharmaceuticals Inc.: Aurinia Announces Positive CHMP Opinion for LUPKYNIS (voclosporin) for the Treatment of Adults with Active Lupus Nephritis in Europe
Positive CHMP opinion is based on a comprehensive submission including data from the pivotal AURORA 1 efficacy study and the AURORA 2 continuation study, demonstrating voclosporin to be safe and well
Source: finanznachrichten.de
Tris Pharma Announces Publication of Study Results Highlighting the Efficacy and Safety of DYANAVEL® XR (amphetamine) Tablets for the Treatment of the Symptoms of ADHD in Adults
Tris announces the publication of a Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of DYANAVEL XR Tablets in Adults with ADHD in the Journal of...
Tris Pharma Inc Prnewswire Tris Pharma Inc Fixed Dose Study Clinical Psychiatry Permanent Product Measure Tris Pharma
Source: prnewswire.com